Munich/Martinsried (pta043/06.04.2020/22:00) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, announces today that it was granted patents from the Japanese Patent Office (JP6676759) and from the New Zealand Patent Office (NZ741954). The patents cover the novel CrossTAg-1 technology that allows cross-presentation of antigens on both class I and II Major Histocompatibility Complex (MHC) molecules, also called "Human Leukocyte Antigens" (HLA) in humans.
Medigene believes that CrossTAg-1 is a powerful new technology for dendritic cell vaccine development as it directs short peptides from an antigen to be effectively processed by cellular pathways for both class I and class II HLA presentation, thereby stimulating both cytotoxic T cells and helper T cells, respectively. The activation of these major T cell subsets is a key feature of optimal immune responses, including those against cancer.
The CrossTAg-1 technology can therefore also substantially enhance Medigene's TCR platform as it enables the identification and selection of tumor-specific T cell receptors (TCRs) expressed by both of these key T cell subsets.
Medigene Immunotherapies GmbH and Helmholtz Zentrum München (HMGU) are co-applicants and the patents falls under the main license agreement in place with HMGU.
Prof. Dolores J. Schendel, CEO/CSO of Medigene: "The granted patents are of particular relevance for the further development of our immunotherapies as the novel technology assures that we can activate both helper T cells and cytotoxic T cells specific for peptides derived from the same cancer antigen. In patients, the interaction of both types of T cells is needed for best immunity to ultimately fight and control the cancer."
-------------------------------------------- end of press release ----------------------------------------------
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed bio-technology company headquartered in Martinsried near Munich, Germany. The company is de-veloping highly innovative immunotherapies to target various forms and stages of cancer. Medi-gene concentrates on the development of personalized T cell-based therapies, with a focus on T cell receptor-modified T cells (TCR-Ts) and associated projects currently in pre-clinical and clini-cal development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Dr Gary Waanders, Claudia Burmester, Dr Anna Niedl
Tel.: +49 89 2000 3333 01
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (email@example.com). We will then delete your address from our distribution list.(end)
Lochhamer Straße 11
|contact person:||Medigene PR/IR|
|phone:||+49 - 89 - 20 00 33 - 33 01|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|